Abstract: Despite the benefits of first and second generation anaplastic lymphoma kinase (ALK ) inhibitors in the management of ALK -rearranged advanced non-small-cell lung cancer (NSCLC), the development of acquired resistance poses an ongoing dilemma. Brigatinib has demonstrated a wider spectrum of preclinical activity against crizotinib-resistant ALK  mutant advanced NSCLC. The current review narrates a brief history of tyrosine kinases, the development and clinical background of brigatinib (including its pharmacology and molecular structure) and its use in ALK -positive NSCLC.
Keywords: non-small cell lung cancer, ALK  positive, ALK  inhibitors, brigatinib, TKI